Senride 1& Senride 2
Senride 1 tablet: Each tablet contains Glimepiride BP 1 mg.
Senride 2 tablet: Each tablet contains Glimepiride BP 2 mg.
Senride is indicated as an adjunct to diet and exercise to lower blood glucose in patients with non insulin dependant (Type 2) diabetes mellitus (NIDDM) with hyperglycemia can not be controlled by diet and exercise alone. Senride may be used concomitantly with Metformin when diet exercise, and Glimepiride or Metformin alone do not result in adequate glycemic control. Senride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycemia can not be controlled by diet and exercise or in conjunction with an oral hypoglycemic agent.
DOSAGE AND ADMINISTRATION
There is no fixed dosage regimen for the management of diabetes mellitus with Senride or any other hypoglycemic agent. The initial and the maintenance dosage are set based on results of regular check of glucose in blood and urine. Monitoring of glucose levels in blood and urine also serves to detect either primary or secondary failure of therapy. Usual starting dose: The usual starting dose of Senride as initial therapy is 1-2 mg once daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic agents should be started with 1 mg once daily, and should be titrated carefully. There is no exact dosage relationship between Senride and other oral blood glusoe lowering agents. The maximum starting dose of Senride should be no more than 2 mg. Usual maintenance dose: The usual maintenance dose is 1-4 mg once daily. The maximum recommended dose is 8mg once daily. After reaching of a dose of 2mg, dosage increases should be made in increments of no more than 2mg at 1-2 weeks intervals based upon the patient's blood glucose response. Patients receiving other oral hypoglycemic agents: As with other sulfonylurea hypoglycemic agents, no transition period is necessary when transferring patients to Senride. Patients should be observed carefully (1-2 weeks) for hypoglycemia when being transferred from longer-half life sulfonylureas (e.g. Chlorpropamide) to Senride due to potential overlapping of drug effect.
Glimepiride is contraindicated in patients with
1. Known hypersensitivity to the drug.
2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Patients with impaired renal function may be more sensitive to the glucose-lowering effect of Glimepiride. Debilitated and malnourished patients and those with adrenal, pituitary, or hepatic insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs.
Loss of control of blood glucose: When a patient is stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to add insulin in combination with Glimepiride or even use insulin monotherapy.
Hemolytic anemia: Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Since Glimepiride belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.
Hypoglycemia, nausea, vomiting, diarrhea, abdominal pain, allergic skin reactions e.g. pruritus, erythema and urticaria and blurred vision may be reported.
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including NSAIDs and other drugs that are highly protein bound, such as salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, MAO inhibitors, beta adrenergic blocking agents, and clarithromycin. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include thiazides, and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic drugs leading to severe hypoglycemia has been reported.
USE IN PREGNANCY AND LACTATION
Pregnancy: Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. On the basis of results from animal studies, Glimepiride should not be used during pregnancy. Patients who are planning a pregnancy should consult their physician, and it is recommended that they change over to insulin for the entire course of pregnancy and lactation.
Nursing mothers: Although it is not known whether Glimepiride is excreted in human milk, other sulfonylureas are excreted in human milk. Because the potential for hypoglycemia in nursing infants may exist, Glimepiride should be discontinued in nursing mothers. Insulin therapy should be considered in this situation.
Store in a cool and dry place, protected from light and moisture.
Senride 1 tablet: Each box contains 6×10's tablet in blister pack.
Senride 2 tablet: Each box contains 3×10's tablet in blister pack.